echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > WuXi AppTec announces the completion of the acquisition of OXGENE and continues to strengthen its global service capabilities for cell and gene therapy

    WuXi AppTec announces the completion of the acquisition of OXGENE and continues to strengthen its global service capabilities for cell and gene therapy

    • Last Update: 2021-07-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    WuXi AppTec announced today that it has completed the acquisition of OXGENE, a British gene therapy technology company

    The acquisition will further expand the technical capabilities of WuXi AppTec's cell and gene therapy platform, provide customers with integrated, end-to-end cell and gene therapy product development and production services, and promote innovative therapies to benefit patients worldwide


    Through this acquisition, OXGENE will become a wholly-owned subsidiary of WuXi AppTec, which focuses on cell and gene therapy CTDMO.
    At the same time, OXGENE will retain its original company name and become WuXi’s first R&D and production base in Europe.

    The addition of OXGENE will further enhance WuXi's integrated platform capabilities and accelerate the development, testing, production and commercialization of cell and gene therapy products by empowering global customers, and continue to promote more innovative therapies to enter the market as soon as possible


    Since its establishment in 2011, OXGENE has provided efficient drug discovery and production solutions for the cell and gene therapy industry with its innovative technology, R&D services and powerful large-scale production system

    In addition, OXGENE's new TESSA technology for adeno-associated virus (AAV) production and the XLenti solution for stable production of lentivirus not only improve the production efficiency of cell and gene therapy products, but also significantly reduce costs


    “OXGENE’s new-generation technology platform has successfully solved the complex problems of cell and gene therapy in the production of viral vectors

    ” said Dr.
    Ryan Cawood, founder and CEO of OXGENE.
    “We are very happy to join WuXiGene and work together Strengthen the large-scale application of innovative technologies, continue to expand service capabilities, and help customers significantly increase production capacity and reduce costs, so that more cell and gene therapies can come out as soon as possible, and benefit patients worldwide


    "We very much welcome OXGENE to join

    WuXiGene," said Dr.
    Youxiang Zhang, CEO of WuXiXi.
    "Combined with WuXiXi's leading cell and gene therapy CTDMO platform and OXGENE's cutting-edge innovative technology capabilities, we will bring transformative changes to our customers.

    Through this acquisition, WuXi Biosciences will further enhance the capabilities of cell and gene therapy R&D and production platforms, and continue to empower customers to bring more and better innovative treatment solutions to patients around the world


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.